CannaPharmaRx 3Q 2026: Revenue $137.71K, EPS ($0.00) — 10-Q Summary
CannaPharmaRx reported 3Q 2026 revenue of $137.71K, down 79% YoY, with net income of $645.42K, reversing a prior loss. Lower sales volumes, including no Cantek sales, drove revenue decline, while non-cash gains improved earnings. The company has $32,037 in cash and a $30.93M working-capital deficiency, with management expressing doubt about its ability to continue operations.
How this was made

The 30-second read
Why it matters
For traders, the key decision inputs are the magnitude of the sales decline, the operating expense changes, and the explicit going-concern doubt tied to very low cash and a large working-capital deficiency.
Market read
This is a distressed-company quarterly disclosure with explicit going-concern risk, which can drive near-term repricing and financing/dilution speculation.
What to watch
The company cites capacity expansion plans (10 growing rooms, additional drying/packing) that could support future volumes if liquidity is secured, partially offsetting near-term distress.
Background
The piece summarizes CannaPharmaRx’s 3Q 2026 Form 10-Q, focusing on revenue collapse, operating loss, and liquidity/going-concern language.
Ticker impact
CannaPharmaRx reports 3Q 2026 revenue down 79% and a going-concern warning, with cash of $32,037 and a large working-capital deficiency.
Likely downside pressure as traders price in going-concern risk and potential financing/dilution needs.
The article’s newest facts are the quarter’s revenue/EPS swing and explicit going-concern language, plus very low cash versus a large working-capital deficit.
Market effects
Reinforces weak demand and financing fragility in small-cap cannabis producers, potentially weighing on peer sentiment.
Limited, mostly affects US microcap cannabis names with similar balance-sheet risk.
Low, company-specific filing with no stated cross-border catalyst.
Counterpoint
Non-cash fair-value gains and derivative conversion features improved net income, so the headline profit may not reflect core operating strength.
Key entities
- issuerCannaPharmaRx, Inc.
Reports 3Q 2026 revenue of $137.71K (down 79% YoY) and going-concern doubt in its 10-Q summary.